Literature DB >> 21860099

Is screening patients for antibiotic-resistant bacteria justified in the Indian context?

S Bhattacharya1.   

Abstract

Infection with multi-antibiotic-resistant bacteria is a common clinical problem in India. In some countries and centres, screening patients to detect colonisation by these organisms is used to determine specific interventions such as decolonisation treatment, prophylactic antibiotics prior to surgical interventions or for selection of empirical antibiotic therapy, and to isolate patients so that transmission of these difficult to treat organisms to other patients could be prevented. In India, there is no national guideline or recommendation for screening patients for multi-drug-resistant (MDR) bacteria such as MRSA (methicillin-resistant Staphylococcus aureus), VRE (vancomycin-resistant enterococcus), ESBL (extended spectrum beta-lactamase) or MBL (metallo-beta-lactamase) producers. The present article discusses the relevance of screening patients for multi-antibiotic-resistant bacteria in the Indian context. Literature has been reviewed about antibiotic resistance in India, screening methodology, economic debate about screening. The percentages of strains from various hospitals in India which were reported to be MRSA was between 8 and 71%, those for ESBL between 19 and 60% and carbapenem-resistant Gram-negative bacilli between 5.3 and 59%. There exists culture-based technology for the detection of these resistant organisms from patient samples. For some pathogens, such as MRSA and VRE Polymerase chain reaction-based tests are also becoming available. Screening for MDR bacteria is an option which may be used after appraisal of the resources available, and after exploring possibility of implementing the interventions that may be required after a positive screening test result.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21860099     DOI: 10.4103/0255-0857.83902

Source DB:  PubMed          Journal:  Indian J Med Microbiol        ISSN: 0255-0857            Impact factor:   0.985


  7 in total

1.  Simultaneous gut colonisation and infection by ESBL-producing Escherichia coli in hospitalised patients.

Authors:  Johny Asir; Shashikala Nair; Sheela Devi; Kenchappa Prashanth; Rajagopalan Saranathan; Reba Kanungo
Journal:  Australas Med J       Date:  2015-06-30

2.  Multidrug-Resistance and Extended Spectrum Beta-Lactamase Production in Uropathogenic E. Coli which were Isolated from Hospitalized Patients in Kolkata, India.

Authors:  Mandira Mukherjee; Shreya Basu; Sandip Kumar Mukherjee; Monalisa Majumder
Journal:  J Clin Diagn Res       Date:  2013-03-01

3.  Admission surveillance cultures among patients admitted to intensive care unit.

Authors:  Varsha Gupta; Nidhi Singla; Satinder Gombar; Sanjeev Palta; Tripti Sahoo; Jagdish Chander
Journal:  N Am J Med Sci       Date:  2012-12

4.  Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria?

Authors:  Martin Exner; Sanjay Bhattacharya; Bärbel Christiansen; Jürgen Gebel; Peter Goroncy-Bermes; Philippe Hartemann; Peter Heeg; Carola Ilschner; Axel Kramer; Elaine Larson; Wolfgang Merkens; Martin Mielke; Peter Oltmanns; Birgit Ross; Manfred Rotter; Ricarda Maria Schmithausen; Hans-Günther Sonntag; Matthias Trautmann
Journal:  GMS Hyg Infect Control       Date:  2017-04-10

Review 5.  Surgical Antibiotic Prophylaxis in an Era of Antibiotic Resistance: Common Resistant Bacteria and Wider Considerations for Practice.

Authors:  Bradley D Menz; Esmita Charani; David L Gordon; Andrew J M Leather; S Ramani Moonesinghe; Cameron J Phillips
Journal:  Infect Drug Resist       Date:  2021-12-07       Impact factor: 4.003

6.  Phenotypic Detection of ESBL, AmpC, MBL, and Their Co-occurrence among MDR Enterobacteriaceae Isolates.

Authors:  Thounaojam Salvia; Karma G Dolma; Om Prakash Dhakal; Bidita Khandelwal; Laishram Shantikumar Singh
Journal:  J Lab Physicians       Date:  2022-04-20

7.  High prevalence of extended-spectrum β-lactamase-producing pathogens: results of a surveillance study in two hospitals in Ujjain, India.

Authors:  Ashish Pathak; Yogyata Marothi; Vandana Kekre; Kalpana Mahadik; Ragini Macaden; Cecilia Stålsby Lundborg
Journal:  Infect Drug Resist       Date:  2012-04-05       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.